Neuroscience

Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with ‘Neurophet AQUA’

New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysisAccelerating global expansion with cutting-edge…

4 weeks ago

Wellstack Partners With Hartford HealthCare to Advance Data Integration and Healthcare Analytics

Wellstack and Hartford HealthCare Partner to Drive Innovation in Data Integration and Patient-Centered Care MADISON, WILTZ / ACCESSWIRE / November…

4 weeks ago

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS…

4 weeks ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing…

4 weeks ago

INSIGHTEC SECURES FDA APPROVAL AND CE MARKING FOR EXABLATE® PRIME ON PHILIPS MR SYSTEMS

Philips' MRI scanners are now compatible with Insightec technology to treat patients suffering with essential tremor (ET) and Parkinson's disease.…

4 weeks ago

Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference

MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…

1 month ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Reductions also seen in comorbid anxiety and depression symptomsBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay…

1 month ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…

1 month ago

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in…

1 month ago

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products

Seven new e-trainings, all 30 minutes or less, are available starting today through Allergan Medical Institute® (AMI) at AMIOnline.com IRVINE,…

1 month ago